Citations

Clear

29 citation(s) found for "Siegmund, S".

A novel classification of testicular sex cord‐stromal tumours from the Testicular Sex Cord‐Stromal Tumour ( TESST ) group: a collaboration of the Genitourinary Pathology Society (
Acosta, Andrés , Bremmer, Felix , Jc, Cheville, Colecchia, Maurizio , Comperat, Eva, Cornejo, Kristine, Baydar, Dilek E., Gill, A J, Gonzalez‐Peramato, Maria del Pilar, Gupta, Sounak , Hirsch, Michelle S. , Idrees, Muhammad T., Maclean, Fiona, Mohanty, Sambit K., Raspollini, Maria Rosaria , Sangoi, Ankur R , SHOLL, L B, Siegmund, S, Tickoo, Satish K., Tm, Ulbright, Yilmaz, Asli, Sangoi, Ankur R. , Acosta, Andrés M , Matoso, Andres , Menon, Santosh , Michalova, Kvetoslava , Reyes-Mugica, Miguel , Raspollini, Maria Rosaria , Sangoi, Ankur R , Tsuzuki, Toyonori , Berney, Daniel M , Sangoi, Ankur R , Compérat, Éva , Cornejo, Kristine M. , Baydar, Dilek Ertoy , González-Peramato, María Pilar, Idrees, Muhammad T. , Kao, Chia‐Sui , Maclean, Fiona M. , Mehra, Rohit, Mohanty, Sambit K. , Reyes‐Múgica, Miguel , Siegmund, Sophie C., Tickoo, Satish K. , Tsuzuki, Toyonori , Ulbright, Thomas M. , Williamson, Sean R. , Yilmaz, Aslı , Berney, Daniel M.

Mayo Clinic

Histopathology | July 9, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/his.70207 | PMID 42421431 Get It

Aims Testicular sex cord‐stromal tumours (TSCSTs) are rare neoplasms that arise from (or show differentiation to) elements derived from the sex cords or intertubular stroma. The current classification (World Health Organization, 2022) is based almost entirely on morphology, with many tumour types such as granulosa cell tumours being defined based on their resemblance to ovarian counterparts. Recent studies have uncovered new clinicopathological, molecular and biological nuances within this group of tumours, underscoring differences with ovarian homologues. Methods and results Considering the new data, a group of genitourinary pathology experts (Testicular Sex Cord‐Stromal Tumour [TESST] group) has proposed a revised ‘TESST classification’ that incorporates the best available evidence. This classification is structured and hierarchical, composed of the following tiers: (1) group, (2) category, (3) entity and (4) histological pattern. ‘Group’ refers to the histological compartment a specific tumour belongs to (sex cords, stroma or both), whereas ‘category’ is defined by the phenotype of the tumour, taking non‐neoplastic elements of the ovary and testis as a reference. The third tier, ‘entity’, refers to neoplasms with shared clinicopathological and/or molecular features that justify classifying them as distinct types. Lastly, ‘histological patterns’ are recurrent morphological variations within entities that are not linked to distinct clinicopathological or molecular features. Conclusions We propose a classification that will provide a framework to improve current clinical management and guide future research in the field.
P171 Efficacy and safety of icotrokinra, a targeted oral peptide that blocks il-23 receptor activation, in ulcerative colitis: results from ANTHEM-UC
Limdi, Jimmy, Jairath, Vipul, Siegmund, Britta, Surace, Lindsey, Erondu, Ngozi, Chen, Minhu, Chachu, Karen, Louis, Edouard, Matsuoka, Katsuyoshi, Houck, Nicole, Frustaci, Mary Ellen, Zhan, Joyce, Rydzewska, G, VLoftus, Edward, Abreu, M T, Jairath, Vipul , Siegmund, Britta, Erondu, Ngozi, Chachu, Karen A., Matsuoka, Katsuyoshi , Arthur, Edmund, Frustaci, Mary Ellen, Rydzewska-Wyszkowska, Grażyna

Mayo Clinic

E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A188-A188

10.1136/gutjnl-2026-bsg.299 Get It

O60 Icotrokinra, a targeted oral peptide that blocks IL-23 receptor activation, in moderate-to-severe ulcerative colitis: week 12 results from ANTHEM-UC
Limdi, Jimmy, Abreu, M T, Siegmund, Britta, Surace, Lindsey, Erondu, Ngozi, Chen, Minhu, Chachu, Karen, Louis, Edouard, Matsuoka, Katsuyoshi, Houck, Nicole, Frustaci, Mary Ellen, Zou, Bin, Rydzewska, G, Loftus, Edward V, Jairath, Vipul, Siegmund, Britta, Erondu, Ngozi, Chachu, Karen A., Matsuoka, Katsuyoshi , Arthur, Edmund, Frustaci, Mary Ellen, Zou, Bin , Rydzewska-Wyszkowska, Grażyna , Loftus, Edward V , Jairath, Vipul

Mayo Clinic

Oral Abstracts | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A38-A39

10.1136/gutjnl-2026-bsg.59 Get It

OP29 Icotrokinra, the first targeted oral peptide that selectively blocks the interleukin-23 receptor, reduces systemic and tissue inflammatory burden in Ulcerative Colitis: Results from the ANTHEM-UC study
Louis, E, Jairath, V, Siegmund, Britta, Kannan, A K, Zeeman, Martha , Hart, Ailsa, Strawn, D, Venkat, S, Tomsho, L, Mcrae, Bradford, Ruane, D, Surace, Lindsey, Erondu, N, Zhan, J, Chen, M, Chachu, K, Matsuoka, K , Limdi, J, Rydzewska, G, Abreu, M T, Loftus, E V, Jairath, Vipul , Hart, Ailsa , Strawn, David, Venkat, Swati , Tomsho, Lynn, McRae, Bradford L., Ruane, D, Erondu, Ngozi, Zhan, Joyce, Chen, M , Chachu, Karen A., Limdi, J, Rydzewska-Wyszkowska, Grażyna , Loftus, E

Mayo Clinic

Journal of Crohn’s and Colitis | January 21, 2026 | Volume: 20 | Issue: Supplement_1 | Pages: No page available

10.1093/ecco-jcc/jjaf231.029 Get It

Abstract Background Icotrokinra is the first targeted oral peptide that selectively blocks the IL-23 receptor (IL-23R) and precisely inhibits the IL-23 pathway. In ANTHEM-UC—a Phase 2b, randomised, double-blind, placebo (PBO)-controlled, dose-ranging study in adults with moderately to severely active ulcerative colitis (UC)—all doses of icotrokinra achieved the primary endpoint of clinical response and delivered clinically meaningful improvements across key secondary endpoints at Week (W)12,1 which were maintained or improved at W28.2 Here we report the impact of icotrokinra on systemic and tissue biomarkers of inflammatory burden in UC. Methods Participants were randomised (1:1:1:1) to receive once-daily icotrokinra 100 mg, 200 mg, 400 mg, or PBO. Clinical inflammatory biomarkers, C-reactive protein (CRP) and faecal calprotectin (FCP), along with serum IL-23 pathway biomarkers (IL-22, IL-17A, and IL-17F) were used to determine the impact of icotrokinra on systemic inflammation. Gene expression changes in colonic biopsies were used to confirm tissue IL-23 pathway engagement and dampening of tissue inflammation with icotrokinra. Results At the W12 primary timepoint, all doses of icotrokinra attenuated levels of serum CRP and FCP (Figure 1). All doses of icotrokinra, but not PBO, markedly reduced serum levels of IL-22, IL-17A, and IL-17F at W12 relative to baseline. Greater reductions in these serum biomarkers of IL-23 pathway activation were observed with the 200 mg and 400 mg doses relative to the 100 mg dose (Figure 1, nominal p < 0.05). All doses of icotrokinra, but not PBO, markedly reduced expression of gene sets associated with the IL-23–driven inflammation in tissue at W12 relative to baseline (Figure 2, nominal p < 0.0001). With icotrokinra treatment, the tissue transcriptome more closely resembled that of healthy individuals, with decreased expression of gene sets associated with UC-relevant inflammatory cell types and increased expression of genes characteristic of healthy epithelial cells. Importantly, dampening of systemic and tissue inflammation with icotrokinra was sustained at W28 (Figures 1 & 2). Conclusion We show for the first time that blocking the IL-23R can inhibit IL-23-mediated inflammatory signaling in UC patients. Icotrokinra treatment induced a sustained (W28) reduction in systemic and tissue biomarkers of inflammatory burden in UC. Furthermore, icotrokinra induced transcriptional changes that are consistent with dampening of IL-23–driven inflammation and normalization of the tissue transcriptome. While all once-daily doses of icotrokinra attenuated systemic and tissue inflammation, greater reduction of systemic inflammatory burden was observed with the 200 mg and 400 mg doses of icotrokinra. References: 1. Abreu MT, et al. United European Gastroenterol J. 2025 10;13(suppl 8):172-3. 2. Jairath V, et al. Am J Gastroenterol. 2025 120;10(suppl 2):S312. Conflict of interest: Louis, Edouard: Education and Research Grants for my department: Abbvie, Takeda, Janssen, Pfizer, Fresenius-Kabi, Celltrion, EG pharma, Sandoz, Falk Personal Fees for conferences, advisory boards and consultancy: Abbvie, Takeda, Ferring, Pfizer, Janssen, Lilly, Galapagos, Celltrion, Arena, BMS, Falk, Biokuris, Fresenius-Kabi, Thabor Jairath, Vipul: Consulting fees from AbbVie, Alimentiv, Amgen, Anaptys Bio, Asahi Kasei, Asieris, Astra Zeneca, Attovia, Blackbird Labs, Bristol Myers Squibb, Boehringer Ingleheim, Biomebank, Caldera, Calluna, Catalytic Health, Celltrion, Ensho, Enthera, Exeliome Biosciences, Ferring, Fresenius Kabi, Gilead, Granite Bio, GSK, Johnson & Johnson, Lilly, Merck, Mountainfield, MRM Health, Nxera, Organon, OSE Immunotherapeutics, Pendopharm, Pioneering Medicine, Pfizer, Prometheus, Roche/Genentech, Sanofi, SCOPE, Shattuck Labs, Sorriso, Spyre, Synedgen, Takeda, Teva, Tillotts, Union Therapeutics, Ventus, Ventyx, Vividion, Xencor, Zealand Pharma. Siegmund, Britta: Consultant for AbbVie, Abivax, Boehringer Ingelheim, Bristol Myers Squibb, Dr. Falk Pharma, Eli Lilly, Endpoint Health, Galapagos, Johnson & Johnson, Materia Prima, MSD, Pfizer, Takeda, Wedbush Securities speaker for AbbVie, AlfaSigma, Bristol Myers Squibb, CED Service GmbH, Dr. Falk Pharma, Eli Lilly, Ferring, Galapagos, Johnson & Johnson, MD Education, MSD, Pfizer, Tr1xBio grant from Pfizer. Kannan, Arun K: Employee and shareholder of Johnson & Johnson Zeeman, Martha: Employee and shareholder of Johnson & Johnson Hart, Amy: Employee and shareholder of Johnson & Johnson Strawn, David: Employee and shareholder of Johnson & Johnson Venkat, Swati: Employee and shareholder of Johnson & Johnson Tomsho, Lynn: Employee and shareholder of Johnson & Johnson Mcrae, Bradford: Employee and shareholder of Johnson & Johnson Ruane, Darren: Employee and shareholder of Johnson & Johnson Surace, Lindsey: Employee and shareholder of Johnson & Johnson Erondu, Ngozi: Employee and shareholder of Johnson & Johnson Zhan, Joyce: Employee and shareholder of Johnson & Johnson Chen, Minhu: I have received speaker honoraria from Takeda China, Xian Janssen, and AbbVie China, as well as research funding from Takeda (China). Chachu, Karen: Advisory board for Johnson & Johnson consultant for OptumRx Matsuoka, Katsuyoshi: Grant: Abbvie Inc., Mochida Pharmaceutical Co., Ltd., ZERIA Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., JIMRO Co., Ltd. Personal Fees: Mitsubishi Tanabe Pharma, Janssen Pharmaceutical K.K., Abbvie Inc., EA Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Mochida Pharmaceutical Co., Ltd., ZERIA Pharmaceutical Co., Ltd., Nippon Kayaku Co., Ltd., Pfizer Inc., Kyorin Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Kissei Pharmaceutical Co., Ltd., Gilead Sciences, Celltrion Healthcare, Bristol-Myers Squibb Limdi, Jimmy: Speaker/consultancy fees from AbbVie, Abivax, Arena, BioHit, Bristol Myers Squibb, Celltrion, Eli Lilly, Ferring, Galapagos, Johnson & Johnson, MSD, Pfizer, Takeda research support from Galapagos, Takeda Rydzewska, Grazyna: Speaker and consultant fees from AbbVie, AlfaSigma, AstraZeneca, Bayer, Biocodex, Bristol Myers Squibb, Ferring, Johnson & Johnson, Lilly, PRO.MED.Pl, Recordati, Sanprobi, SOBI, Takeda travel/accommodation meeting expenses from AbbVie, Ferring, Takeda Abreu, Maria Teresa: Grant/Research Support: Janssen, Prometheus Bioscience, Takeda Consultant: Janssen, Prometheus Bioscience, Takeda Gilead, Eli Lilly, AbbVie Inc., Bristol Myers, Imedex, Loftus Jr, Edward V: Consultant/advisory board member for AbbVie, Amgen, Bristol Myers Squibb, Eli Lilly and Company, Genentech, Gilead Sciences, Johnson & Johnson, Pfizer, Takeda, UCB.
Efficacy of Mirikizumab in Comparison to Ustekinumab in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3 VIVID-1 Study
Ferrante, M., Kaser, Arthur , Reinisch, Walter, Bragg, S. M., Lin, Zhantao, Lopes, Michelle Ugolini, Protić, Marijana , Jairath, Vipul , Sands, Bruce E , Bossuyt, Peter , Farraye, Francis A. , Hisamatsu, T., Kierkuś, Jarosław , Laharie, David , Siegmund, Britta , Hon, Kam‐Lun Ellis , Morris, Nathan , Danese, Silvio

Mayo Clinic

Zeitschrift für Gastroenterologie | November 27, 2025 | Volume: 62 | Issue: 05 | Pages: e481-e482

10.1055/s-0044-1786891 Get It

Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis
Colombel, J.F., Ponich, Terry, Longman, Randy , Алексеева, О. П., Marta, Carmen-Ioana, Charles, Lorna, Rubin, DT, Afzali, Anita , Siegmund, Britta , Danese, Silvio , Jovanović, Igor , Bossuyt, Patrick M. , Petersen, Anne Sohrt , Loftus, Edward V. , Wolf, Douglas C.

Mayo Clinic

Zeitschrift für Gastroenterologie | November 25, 2025 | Volume: 60 | Issue: 08 | Pages: e428-e428

10.1055/s-0042-1754606 Get It

International consensus on the use of intestinal ultrasound in inflammatory bowel disease trials
Allocca, Mariangela , Sands, Bruce E, Caron, Bénédicte , Laurent, Valérie, Novák, K, Panaccione, Remo , Bossuyt, Peter , Bruining, David H. , Joel, Fletcher, Hart, Ailsa , Kobayashi, Taku , Cleveland, Noa Krugliak , Kucharzik, Torsten , Laghi, Andrea , Lakatos, Péter L. , Leong, Rupert W. , Louis, Édouard , Siegmund, Britta , Vavricka, Stephan R. , Stoker, Jaap , Peyrin-Biroulet, Laurent, Jairath, V , Novak, Kerri , Panaccione, Remo , Bossuyt, Peter , Fletcher, Joel G , Fumery, Mathurin , Halfvarson, Jonas , Kobayashi, Taku , Lakatos, Peter L , Leong, Rupert W , Loftus, Edward V , Sebastian, Shaji , Siegmund, Britta , Vavricka, Stephan R , Stoker, Jaap , Rimola, Jordi , Danese, Silvio , Jairath, Vipul , Rubin, David T. , Laurent, V., Novak, Kerri L. , Dignass, Axel , Dotan, Iris , Furfaro, Federica , Loftus, Edward V. , Louis, Edouard , Magro, Fernando , Olivera, Pablo Andres , Wilson, Stephanie R. , Rimola, Jordi , Peyrin‐Biroulet, Laurent , Danese, Silvio

Mayo Clinic

Journal of Crohn's and Colitis | September 15, 2025 | Volume: 19 | Issue: 9 | Pages: No page available

10.1093/ecco-jcc/jjaf170 | PMID 40973472 Get It

Abstract Background and Aims Intestinal ultrasound (IUS) is increasingly used to monitor treatment efficacy in inflammatory bowel disease (IBD) trials. However, standardized definitions for response, remission, and optimal assessment timing remain undefined. An international expert consensus meeting was held to establish IUS endpoints for clinical trials. Methods A panel of 35 international gastroenterologists and radiologists participated in a modified Delphi process, reviewing the literature and developing consensus statements. Agreement was defined as at least 75% consensus. Results Consensus was reached on 150 statements across four domains: general IBD (30 statements), luminal Crohn’s disease (CD) (43), perianal CD (51), and ulcerative colitis (UC) (26). For luminal CD and UC, ultrasound response was defined by: (1) a ≥25% reduction in bowel wall thickness (BWT) from baseline, or (2) multifactorial improvement, combining BWT reduction with ≥1 grade decrease in color Doppler signal (CDS) or another IUS parameter. Assessments were set at weeks 4-8 for the colon and week 12 for the terminal ileum. Ultrasound remission in luminal CD was defined as: (1) BWT normalization (≤3 mm) or (2) normalization of multiple parameters, including BWT, CDS, and all other IUS parameters. Similar remission criteria were proposed for UC, but the sigmoid BWT normal range (3-4 mm) remained uncertain. The bowel ultrasound score (BUSS) for CD and the Milan ultrasound criteria (MUC) for UC were supported as standardized scoring systems for trials. Conclusion This consensus provides standardized IUS definitions to enhance consistency in IBD trials, supporting the integration of IUS in future research.
Effects of mirikizumab versus placebo on histologic inflammation evaluated by comprehensive assessment in 5 intestinal segments in a randomized controlled phase 3 trial of participants with Crohn’s disease
Feagan, Brian, D’Haens, Geert , Pai, Rish K. , Protić, Marijana , Escobar, Rodrigo , Reinisch, Walter, Jairath, Vipul , Magro, Fernando , Hertogh, Gert D. , Harpaz, Noam , Hisamatsu, T, Hon, Kam‐Lun Ellis , Owen, C, Reinisch, Walter , Siegmund, Britta

Mayo Clinic

Zeitschrift für Gastroenterologie | September 4, 2025 | Volume: 63 | Issue: No issue available | Pages: No page available

10.1055/s-0045-1810728 Get It

P57 Efficacy of risankizumab versus ustekinumab by disease duration in moderate-to-severe crohn’s disease: phase 3 SEQUENCE post-hoc analysis
Peyrin-Biroulet, Laurent, Ben‐Horin, Shomron, Ha, Christina , Aponte, Fernando, Kligys, Kristina, Zambrano, Javier , Anschutz, Toni , Garrison, Andrew, Peyrin‐Biroulet, Laurent , Ben‐Horin, Shomron , Siegmund, Britta , Colombel, Jean‐Frédéric

Mayo Clinic

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A123.2-A124

10.1136/gutjnl-2025-bsg.193 Get It